nonvalvular atrial fibrillation
et "Cost-effectiveness of edoxaban versus al, rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US," ClinicoEconomics and Outcomes Research, pp.
et "Cost-effectiveness of edoxaban versus al, rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation ( NVAF ) in the US," ClinicoEconomics and Outcomes Research, pp .